Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Yumeng Zhang, Daniel DeAvila, Fatima Tuz Zahra, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Leidy Isenalumhe, Lubomir Sokol, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 8017.

https://doi.org/10.1182/blood-2025-8017

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Fnu Amisha, Syeda Saba Kareem, Kiranpreet Kaur, Biwei Cao, Samuel Reynolds, Yumeng Zhang, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Javier Pinilla-Ibarz, Lubomir Sokol, Bijal Shah, Frederick Locke, Julio Chavez, Michael Jain

Blood (2025) 146 (Supplement 1): 5512.

https://doi.org/10.1182/blood-2025-5512

Published: 2025

Journal Articles

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Abida Babu, syeda mahrukh naqvi, Julio Chavez, Bijal Shah, Celeste Bello, Leidy Isenalumhe, Sameh Gaballa, Yumeng Zhang, Javier Pinilla-Ibarz, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2025-1825

Published: 2025

Journal Articles

Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)

Sagar Patel, Elise Chong, Farah Toron, Fei Fei Liu, Fangyi Gu, John Baird, Sameh Gaballa

Blood (2025) 146 (Supplement 1): 6270.

https://doi.org/10.1182/blood-2025-6270

Published: 2025

Journal Articles

A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras

Mostafa Eysha, David Elliott, Alaaeddine El Ghazawi, Jackson Twyman, Mohanad Elchouemi, Arsalan Asad, Ekrem Turk, Sameh Gaballa

Blood (2025) 146 (Supplement 1): 3911.

https://doi.org/10.1182/blood-2025-3911

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Fnu Amisha, Jessica Shostak, Wenyi Fan, Onyee Chan, Rory Shallis, Zhuoer Xie, Alison Walker, Sameh Gaballa, Javier Pinilla-Ibarz, Eric Padron, David Sallman, Bijal Shah, Julio Chavez, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Yumeng Zhang, Todd Knepper, Andrew Kuykendall

Blood (2025) 146 (Supplement 1): 3531.

https://doi.org/10.1182/blood-2025-3531

Published: 2025

Journal Articles

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Sushmita Khadka, Anushi Patel, Jonathan Zhao, Leidy Isenalumhe, Lubomir Sokol, Sameh Gaballa, Yumeng Zhang, Celeste Bello, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 1882.

https://doi.org/10.1182/blood-2025-1882

Published: 2025

Journal Articles

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Yumeng Zhang, Jongphil Kim, Richard Corona, Shannen Whiddon, Janice Bennett, Anthony Suda, Bijal Shah, Celeste Bello, Julio Chavez, Leidy Isenalumhe, Sameh Gaballa, Javier Pinilla-Ibarz, Frank Glass, Lubomir Sokol

Blood (2025) 146 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2025-1881

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Blood (2024) 144 (Supplement 1): 868.

https://doi.org/10.1182/blood-2024-193681

Published: 2024

Journal Articles

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Blood (2024) 144 (Supplement 1): 341.

https://doi.org/10.1182/blood-2024-193589

Published: 2024

Journal Articles

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Sameh Gaballa, Mei Xue, Todor I Totev, Yan Meng, Swetha Challagulla, Zhuo Chen, Keri Yang

Blood (2024) 144 (Supplement 1): 3655.

https://doi.org/10.1182/blood-2024-204187

Published: 2024

Journal Articles

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Rebecca Albuquerque, Anna Shamis, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick L. Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7734.

https://doi.org/10.1182/blood-2024-208905

Published: 2024

Journal Articles

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

Anna Shamis, Rebecca Albuquerque, Athanasios Tsalatsanis, Ambuj Kumar, Zain Ahmad, Hasiq Ovais, Aleksandr Lazaryan, Farhad Khimani, Rawan Faramand, Ciara Louise Freeman, Bijal D Shah, Sameh Gaballa, Julio C. Chavez, Fabiana Perna, Jose L. Ochoa-Bayona, Frederick Locke, Michael D. Jain, Taiga Nishihori, Abu-Sayeef Mirza

Blood (2024) 144 (Supplement 1): 7733.

https://doi.org/10.1182/blood-2024-208743

Published: 2024

Journal Articles

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Mohammad Ammad Ud Din, Katherine Tobon, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Ariel Grajales-Cruz, Kenneth H. Shain, Lubomir Sokol, Bijal D Shah, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2024-208769

Published: 2024

Journal Articles

Continuity of Care for Patients with Chronic Lymphocytic Leukemia: An Analysis of Real-World Data

Sameh Gaballa, Manoj Khanal, Yongmei Chen, Naleen Raj Bhandari, Katherine B. Winfree, Sarang Abhyankar, Lisa M. Hess

Blood (2024) 144 (Supplement 1): 5033.

https://doi.org/10.1182/blood-2024-203246

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Toxicity profile of epcoritamab and glofitamab in aggressive B-cell lymphoma: A real-world analysis of CRS and icans in a single-center cohort

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience

Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience

Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)

A decade of progress: A comparative analysis of real-world survival in chronic lymphocytic leukemia across therapeutic eras

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Clinical and genomic landscape of STAT5B mutations in lymphoid and myeloid malignancies

Treatment related outcomes of very old (>85 years) diffuse large b-cell lymphoma patients.

Trial in progress: A phase I/ib dose-finding study of ropeginterferon alfa-2b (P1101) in patients with cutaneous T-cell lymphoma (CTCL)

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients

Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma

Patient Medication Preferences in Follicular Lymphoma (FL) in the United States (USA): A Discrete-Choice Experiment (DCE)

Impact of Neurological and Psychiatric Comorbidities on Toxicity and Outcomes of Patients with DLBCL Who Receive Axicabtagene Ciloleucel

Impact of Autoimmune Disease on Toxicity and Outcomes after Axicabtagene Ciloleucel in Patients with Diffuse Large B Cell Lymphoma

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Continuity of Care for Patients with Chronic Lymphocytic Leukemia: An Analysis of Real-World Data

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only